Jeff Schell is the President & CEO of TranS1, a company focused on crafting products that solve spinal pathologies leading to excellent patient outcomes with minimal tissue trauma. TranS1 recently conducted an economic analysis of its AxiaLIF which identified many benefits including cost savings. In this podcast, Jeff discusses the study and AxiaLIF.
Tell Us What You Think!